Lusutrombopag: First Global Approval.

Article Details

Citation

Copy to clipboard

Kim ES

Lusutrombopag: First Global Approval.

Drugs. 2016 Jan;76(1):155-8. doi: 10.1007/s40265-015-0525-4.

PubMed ID

26666417 [ View in PubMed

]

Abstract

Lusutrombopag (Mulpleta(R)) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. In September 2015, lusutrombopag received its first global approval in Japan for the improvement of CLD-associated thrombocytopenia in patients scheduled to undergo elective invasive procedures. This article summarizes the milestones in the development of lusutrombopag leading to this first approval.

DrugBank Data that Cites this Article

Drugs

Lusutrombopag

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Lusutrombopag	Thrombopoietin receptor	Protein	Humans	Yes	Agonist	Details